Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soq ...

Corvus Corporate Presentation August 2024 Focus on ITK Inhibitors with Broad Opportunities in Cancer & Immune Diseases Forward-Looking Statements / Safe Harbor 2 This presentation and the accompanying oral presentation contain "forward‐looking" statements, including statements related to the potential safety and efficacy of soquelitinib, ciforadenant and mupadolimab; the Company's ability and Angel Pharmaceutical's ability to develop and advance product candidates into and successfully complete preclinical ...

Financial Data and Key Metrics Changes - Research and development expenses for Q2 2024 totaled $4.1 million, slightly up from $4.0 million in Q2 2023 [3] - The net loss for Q2 2024 was $4.3 million, a decrease from a net loss of $6.5 million in Q2 2023 [4] - Cash, cash equivalents, and marketable securities as of June 30, 2024, amounted to $47.3 million, compared to $27.1 million at the end of 2023 [5] Business Line Data and Key Metrics Changes - The company is advancing its lead ITK inhibitor, soquelitinib, which is showing potential in treating a range of immune diseases and cancers [6][7] - The Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis is currently enrolling patients, with early signs of clinical activity observed [9][10] - In the Phase 3 eligible patients for peripheral T-cell lymphoma (PTCL), the objective response rate (ORR) remains at 39%, with a complete response rate of 26% [12][13] Market Data and Key Metrics Changes - The company is preparing to begin enrollment in a registrational Phase 3 clinical trial for soquelitinib in relapsed PTCL in September 2024 [14] - The FDA has granted Orphan Drug designation and Fast Track designation for soquelitinib for the treatment of relapsed T-cell lymphoma [14] Company Strategy and Development Direction - The company is focusing on the development of selective ITK inhibition as a new therapeutic modality for various immune diseases and cancers [6][7] - There is a strong emphasis on advancing soquelitinib in both immune diseases and cancer, with ongoing discussions for potential partnerships to enhance program efficiency [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of soquelitinib and its unique mechanism of action, which may address a wide range of immune and inflammatory diseases [10][19] - The company anticipates important clinical milestones for soquelitinib in the remainder of 2024, including interim results from the atopic dermatitis trial and the initiation of the Phase 3 trial for PTCL [19][20] Other Important Information - The company has raised $30.3 million in financing in May 2024, which is expected to provide a cash runway into the fourth quarter of 2025 [5] - The company is also advancing second- and third-generation ITK inhibitors, with potential clinical studies expected in 12 to 15 months [38] Q&A Session Summary Question: Expectations for Phase 1 data from atopic dermatitis - Management expects to report safety and efficacy data on the first two cohorts of the clinical trial by Q4, aiming for a majority of patients to show over 50% improvement in EASI scores [22][23] Question: Patient baseline for Phase 1 atopic dermatitis study - Management indicated that the patient mix could include those with prior biologics and those with multiple prior lines of therapy, making it difficult to predict the exact baseline [28] Question: Rationale for selecting renal cell cancer as the first solid tumor - The choice was based on renal cell cancer being an immune-responsive disease, with prior mouse data showing effectiveness against tumors resistant to anti-PD-1 therapy [30][32] Question: Strategic decisions regarding partnerships for expanding programs - Management is actively pursuing partnerships while pushing forward with both immune diseases and cancer programs as quickly as possible [34] Question: Timeline for the pivotal Phase 3 study - The Phase 3 trial is set to start in September, with an interim analysis expected about a year after enrollment begins [47]

Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market Table of Contents- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri ...

Financial Performance - Corvus Pharmaceuticals reported a net loss of $4.3 million for Q2 2024, an improvement from a net loss of $6.5 million in Q2 2023[9]. - The net loss for the quarter was $4,262,000, a decrease from a net loss of $6,503,000 in the same quarter of the previous year, indicating an improvement of 34.4%[20]. - Corvus Pharmaceuticals reported total operating expenses of $5,935,000 for the three months ended June 30, 2024, compared to $5,622,000 for the same period in 2023, reflecting an increase of 5.57%[20]. - The company reported interest income of $434,000 for the quarter, compared to $403,000 in the same quarter of 2023, showing a growth of 7.69%[20]. Cash Position - The company had cash, cash equivalents, and marketable securities of $47.2 million as of June 30, 2024, up from $27.1 million at the end of 2023[8]. - Cash, cash equivalents, and marketable securities increased to $47,246,000 as of June 30, 2024, up from $27,149,000 at the end of 2023, representing a growth of 74.1%[21]. - Corvus anticipates full-year 2024 net cash used in operating activities to be between $24 million and $27 million, projecting a cash balance of $31 million to $34 million by December 31, 2024[8]. - The company expects to fund operations into the fourth quarter of 2025, with estimated net cash used in operating activities for 2024 being a critical focus[19]. Research and Development - Research and development expenses for Q2 2024 totaled $4.1 million, slightly higher than $4.0 million in the same period of 2023[8]. - In the Phase 1/1b trial of soquelitinib for relapsed T cell lymphoma, 39% of evaluable patients (9 out of 23) achieved objective responses, including 26% with complete responses[4]. - The ongoing Phase 1 clinical trial of soquelitinib in atopic dermatitis aims to enroll 64 patients, with initial results showing clinical activity in three evaluable patients[3]. - Corvus plans to initiate a Phase 3 registrational trial for soquelitinib in patients with relapsed peripheral T cell lymphoma in Q3 2024[4]. - Corvus Pharmaceuticals is conducting a Phase 1b/2 clinical trial for mupadolimab in combination with pembrolizumab for patients with advanced head and neck cancers and NSCLC[17]. - Corvus Pharmaceuticals anticipates launching a registrational Phase 3 clinical trial for soquelitinib for PTCL, with specific timelines and patient enrollment targets yet to be detailed[19]. - The company expects to present interim data from the Phase 1 clinical trial of soquelitinib in atopic dermatitis in Q4 2024[3]. Investments and Equity - The company's investment in Angel Pharmaceuticals decreased slightly to $15,404,000 from $16,123,000, a decline of 4.44%[21]. - Corvus Pharmaceuticals has a total of 59,710,265 shares used to compute net loss per share for the quarter, compared to 47,497,414 shares in the same quarter of 2023[20]. - Corvus Pharmaceuticals has a 49.7% equity stake in Angel Pharmaceuticals, with a 7% equity reserved for issuance under the Angel ESOP[18]. Regulatory Designations - The FDA has granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma, and it has received Fast Track designation for relapsed or refractory peripheral T cell lymphoma[4]. - Corvus completed a registered direct offering in Q2 2024, generating $30.3 million in net proceeds[8].

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and ...

BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone acces ...

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company's presentation will be on Wednesday, June 5 at 3:00 p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37719 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Richard Miller - President and CEO, Co-Founder Leiv Lea - Chief Financial Officer Jeffrey Arcara - Chief Business Officer James Rosenbaum - Senior Vice President of Research Ben Jones - Senior Vice President of Regulatory and Pharmaceutical Sciences Conference Call Participants Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Securities Liang Cheng - Jefferie ...